Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.
2.

Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma.

Sie M, den Dunnen WF, Lourens HJ, Meeuwsen-de Boer TG, Scherpen FJ, Zomerman WW, Kampen KR, Hoving EW, de Bont ES.

PLoS One. 2015 Mar 23;10(3):e0122555. doi: 10.1371/journal.pone.0122555. eCollection 2015.

3.

A BCR/ABL-hIL-2 DNA vaccine enhances the immune responses in BALB/c mice.

Qin Y, Tian H, Wang G, Lin C, Li Y.

Biomed Res Int. 2013;2013:136492. doi: 10.1155/2013/136492. Epub 2013 Jun 6.

4.

ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.

Awidi A, Ababneh N, Magablah A, Bsoul N, Mefleh R, Marei L, Abbasi S.

Genet Test Mol Biomarkers. 2012 Nov;16(11):1317-21. doi: 10.1089/gtmb.2012.0147. Epub 2012 Sep 25.

5.

Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.

Capodanno A, Boldrini L, Alì G, Pelliccioni S, Mussi A, Fontanini G.

Oncol Rep. 2012 Nov;28(5):1559-66. doi: 10.3892/or.2012.2017. Epub 2012 Sep 4.

6.

Genetic tests and genomic biomarkers: regulation, qualification and validation.

Novelli G, Ciccacci C, Borgiani P, Papaluca Amati M, Abadie E.

Clin Cases Miner Bone Metab. 2008 May;5(2):149-54.

7.

Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro.

Mokhtari D, Li T, Lu T, Welsh N.

PLoS One. 2011;6(9):e24831. doi: 10.1371/journal.pone.0024831. Epub 2011 Sep 14.

8.

Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.

Tunceroglu A, Matsuda M, Birge RB.

Mol Cancer Ther. 2010 Nov;9(11):3065-73. doi: 10.1158/1535-7163.MCT-10-0623. Epub 2010 Sep 3.

9.

Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner.

Kurokawa T, He G, Siddik ZH.

Cancer Chemother Pharmacol. 2010 Feb;65(3):427-36. doi: 10.1007/s00280-009-1045-2. Epub 2009 Jun 16.

10.

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.

Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, Vigneri P, Nicotera P, Dyer MJ, Holyoake T, Salomoni P, Calabretta B.

J Clin Invest. 2009 May;119(5):1109-23. doi: 10.1172/JCI35660. Epub 2009 Apr 13. Erratum in: J Clin Invest. 2013 Aug 1;123(8):3634.

Supplemental Content

Support Center